Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study. (March 2021)

• Record Type: Journal Article
• Authors: Hashemi, S.; Fransen, M.F.; Niemeijer, A.; Ben Taleb, N.; Houda, I.; Veltman, J.; Becker- Commissaris, A.; Daniels, H.; Crombag, L.; Radonic, T.; Jongeneel, G.; Tarasevych, S.; Looysen, E.; van Laren, M.; Tiemessen, M.; van Diepen, V.; Maassen-van den Brink, K.; Thunnissen, E.; Bahce, I.
• Is Part Of: Lung cancer. Volume 153(2021)
• Page Start: 81
• Page End: 89
• Publication Date: 2021-03
• Subjects: ALK anaplastic lymphoma kinase -- Anti-PD-(L)1 Anti-Programmed Death-(Ligand)1 -- CPS combined positive score -- EGFR epidermal growth factor receptor -- ICI Immune checkpoint inhibitors -- IHC immunohistochemistry -- LDH lactate dehydrogenase -- NLR neutrophils-to-lymphocytes ratio -- NSCLC Non-small cell lung cancer -- OS overall survival -- PFS progression free survival -- PS performance score -- TILs Tumor infiltrating lymphocytes -- TPS tumor proportion score -- UNL upper normal limit; Immunotherapy -- Checkpoint inhibitors -- Non-small cell lung cancer -- Tumor infiltrating lymphocytes -- TIL -- Stroma; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2021.01.013
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Real world datasets are needed to assess biomarker performances in daily routine practice. The stromal CD8+TILs were found to be the strongest predictor for PFS and OS in advanced NSCLC on anti-PD-1 monotherapy. The combination of stromal CD8+TILs, albumin and LDH best predicted OS. Abstract: Introduction: Immune checkpoint inhibitors (ICI), such as anti-PD-1 agents, have become part of the standard of care treatment of advanced non-small cell lung cancer (NSCLC). Predictive biomarkers are needed to identify patients that benefit from anti-PD-1 treatments. Tumor infiltrating lymphocytes (TILs) and PD-L1 are major players in the ICI mechanism of action. In this study, we assess the impact of real-world clinicopathological variables, including TILs and PD-L1, on anti-PD-1 efficacy. Methods: We performed a monocenter retrospective study in advanced NSCLC treated with nivolumab or pembrolizumab between January 2015 and February 2019. The impact of baseline clinical and pathological variables was assessed by univariate and multivariate models. TILs, defined as CD8+T-cells, and PD-L1 were scored in tumor and stroma, and correlated with progression free survival (PFS) and overall survival (OS). Results: We included 366 patients of whom 141 were assessed for tumor and stromal TILs. The median follow-up time was 487 days. In the whole cohort, PFS was associated with high tumor PD-L1, high albumin and good performance. OS was associated with low LDH, high albumin, good performance and 'first-line treatment'. In the TILs subcohort, stromal TILs had the strongest impact on PFS and OS. Stromal TILs were a stronger marker for PFS and OS than tumoral TILs, tumoral PD-L1 or stromal PD-L1. Remaining factors for PFS and OS were albumin and albumin with LDH, respectively. Conclusions: This real-world study on clinicopathological features shows that stromal CD8 + TILs were the strongest predictor for PFS and OS in patients with advanced NSCLC on anti-PD-1 therapy. Other predictors for PFS and OS included albumin and albumin together with LDH, respectively. This study highlights the pivotal role of the stromal compartment in the mechanisms of action of ICI, and the need for further studies aiming to overcome this stromal firewall.